Logo Logo
Hilfe
Hilfe
Switch Language to English

Bonaventura, Aldo; Vecchie, Alessandra; Dagna, Lorenzo; Martinod, Kimberly; Dixon, Dave L.; Tassell, Benjamin W. van; Dentali, Francesco; Montecucco, Fabrizio; Massberg, Steffen; Levi, Marcel und Abbate, Antonio (2021): Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. In: Nature Reviews Immunology, Bd. 21, Nr. 5: S. 319-329

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Here, the authors propose that SARS-CoV-2 induces a prothrombotic state, with dysregulated immunothrombosis in lung microvessels and endothelial injury, which drive the clinical manifestations of severe COVID-19. They discuss potential antithrombotic and immunomodulating drugs that are being considered in the treatment of patients with COVID-19. Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe disease show hyperactivation of the immune system, which can affect multiple organs besides the lungs. Here, we propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels. Microthrombotic complications may contribute to acute respiratory distress syndrome (ARDS) and other organ dysfunctions. Therapeutic strategies aimed at reducing immunothrombosis may therefore be useful. Several antithrombotic and immunomodulating drugs have been proposed as candidates to treat patients with SARS-CoV-2 infection. The growing understanding of SARS-CoV-2 infection pathogenesis and how it contributes to critical illness and its complications may help to improve risk stratification and develop targeted therapies to reduce the acute and long-term consequences of this disease.

Dokument bearbeiten Dokument bearbeiten